Ultragenyx Pharmaceutical Analyst Ratings
Ultragenyx Pharmaceutical (RARE) Receives a Hold From Wedbush
Piper Sandler Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Buy Rating Justified by Strong GTX102 Prospects and Positive Regulatory Outlook
Morgan Stanley Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating
Ultragenyx Pharmaceutical Analyst Ratings
Ultragenyx Pharmaceutical Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating
Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Cooper Co (COO)
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Ultragenyx Pharmaceutical (RARE)
Analysts Conflicted on These Healthcare Names: Canopy Growth (CGC), Ultragenyx Pharmaceutical (RARE) and Roivant Sciences (ROIV)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceutical (RARE)
Buy Rating Affirmed for Ultragenyx Pharmaceutical Based on Clinical Updates and Market Valuation Disconnect
Analysts' Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Illumina (ILMN)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)